DiscGenics, a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, ...
SALT LAKE CITY, April 9, 2025 /PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for ...
Through the International Database on Commodity Tolerance (IDCT), the IAEA gathers and interprets the literature about commodity quality after phytosanitary irradiation treatment. This database should ...
SALT LAKE CITY, Jan. 7, 2019 /PRNewswire/ -- , a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with ...
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of ...
Please provide your email address to receive an email when new articles are posted on . The FDA has given its fast track designation to the investigational cell therapy IDCT for the treatment of ...
The FDA has granted Fast Track designation for IDCT (DiscGenics, Inc.), an investigational cell therapy for the reduction in pain and disability associated with degenerative disc disease (DDD). The ...
DiscGenics, a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback